Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of RO5267683 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: placeboDrug: RO5267683
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01398241
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT01395615
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 322
- Registration Number
- NCT01394276
An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 322
- Registration Number
- NCT01392001
A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01392755
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT01392716
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)
Completed
- Conditions
- Renal Cell Cancer
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01392729
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 443
- Registration Number
- NCT01392742
- Locations
- π§π¬
Mhat - Pleven; Clinic of Gastroenterology, Pleven, Bulgaria
π§π¬Mhat Queenjoanna; Clinic of Gastroenterology, Sofia, Bulgaria
π§π¬Umhat St. Georgi; Clinical of Gastroenterology, Plovdiv, Bulgaria
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Phase 2
Completed
- Conditions
- High Grade Glioma
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 124
- Registration Number
- NCT01390948
- Locations
- π¦πΊ
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
π¦πΊLady Cilento Children's Hospital; Oncology Services Group, Level 12b, South Brisbane, Queensland, Australia
π¨πΏFakultni nemocnice Brno; 2. detska klinika, pracoviste Detska nemocnice, Brno, Czechia
A Study on the Interaction Between Danoprevir/Ritonavir and Methadone
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01389544
Β© Copyright 2025. All Rights Reserved by MedPath